PL209419B1 - Zastosowanie peptydów lub białek do wytwarzania leku do terapeutycznego i/lub profilaktycznego stosowania w przypadku zapaleń w medycynie i/lub weterynarii - Google Patents

Zastosowanie peptydów lub białek do wytwarzania leku do terapeutycznego i/lub profilaktycznego stosowania w przypadku zapaleń w medycynie i/lub weterynarii

Info

Publication number
PL209419B1
PL209419B1 PL362924A PL36292401A PL209419B1 PL 209419 B1 PL209419 B1 PL 209419B1 PL 362924 A PL362924 A PL 362924A PL 36292401 A PL36292401 A PL 36292401A PL 209419 B1 PL209419 B1 PL 209419B1
Authority
PL
Poland
Prior art keywords
peptides
pro
ndsk
arg
medicament
Prior art date
Application number
PL362924A
Other languages
English (en)
Polish (pl)
Other versions
PL362924A1 (en
Inventor
Peter Petzelbauer
Original Assignee
Fibrex Medical Res & Dev Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrex Medical Res & Dev Gmbh filed Critical Fibrex Medical Res & Dev Gmbh
Publication of PL362924A1 publication Critical patent/PL362924A1/xx
Publication of PL209419B1 publication Critical patent/PL209419B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL362924A 2000-12-12 2001-12-07 Zastosowanie peptydów lub białek do wytwarzania leku do terapeutycznego i/lub profilaktycznego stosowania w przypadku zapaleń w medycynie i/lub weterynarii PL209419B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT20632000 2000-12-12
PCT/AT2001/000387 WO2002048180A2 (de) 2000-12-12 2001-12-07 Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels

Publications (2)

Publication Number Publication Date
PL362924A1 PL362924A1 (en) 2004-11-02
PL209419B1 true PL209419B1 (pl) 2011-08-31

Family

ID=3689750

Family Applications (2)

Application Number Title Priority Date Filing Date
PL362924A PL209419B1 (pl) 2000-12-12 2001-12-07 Zastosowanie peptydów lub białek do wytwarzania leku do terapeutycznego i/lub profilaktycznego stosowania w przypadku zapaleń w medycynie i/lub weterynarii
PL390342A PL209752B1 (pl) 2000-12-12 2001-12-07 Zastosowanie peptydów lub białek do wytwarzania leku do leczenia chorób zapalnych o podłożu zakaźnym

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL390342A PL209752B1 (pl) 2000-12-12 2001-12-07 Zastosowanie peptydów lub białek do wytwarzania leku do leczenia chorób zapalnych o podłożu zakaźnym

Country Status (30)

Country Link
US (4) US7271144B2 (enExample)
EP (2) EP1341819B1 (enExample)
JP (1) JP4181874B2 (enExample)
KR (1) KR100864069B1 (enExample)
CN (2) CN1518558B (enExample)
AT (2) ATE329614T1 (enExample)
AU (1) AU2002221316A1 (enExample)
BG (1) BG107891A (enExample)
BR (1) BR0116122A (enExample)
CA (1) CA2430972C (enExample)
CY (2) CY1106108T1 (enExample)
CZ (1) CZ20031630A3 (enExample)
DE (2) DE50114771D1 (enExample)
DK (2) DK1586586T3 (enExample)
EA (1) EA005576B1 (enExample)
EE (1) EE200300283A (enExample)
ES (2) ES2323963T3 (enExample)
HR (1) HRP20030564A2 (enExample)
HU (1) HUP0401536A3 (enExample)
IL (2) IL156360A0 (enExample)
MX (1) MXPA03005218A (enExample)
NO (1) NO330767B1 (enExample)
NZ (1) NZ550619A (enExample)
PL (2) PL209419B1 (enExample)
PT (2) PT1341819E (enExample)
SI (2) SI1586586T1 (enExample)
SK (1) SK7062003A3 (enExample)
WO (1) WO2002048180A2 (enExample)
YU (1) YU53803A (enExample)
ZA (1) ZA200304545B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430972C (en) 2000-12-12 2014-08-05 Fibrex Medical Research & Development Gmbh Fibrin fragments for treating inflammation
WO2006000007A1 (de) * 2004-06-25 2006-01-05 Fibrex Medical Research & Development Gesmbh Verwendung von peptiden, die aus der a alpha oder der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock
FR2879604B1 (fr) * 2004-12-22 2010-08-13 Biomerieux Sa Peptides citrullines derives de la fibrine reconnus par des auto-anticorps specifiques de la polyarthrite rhumatoide, et leurs utilisations
AT502987A1 (de) 2005-12-23 2007-07-15 Fibrex Medical Res & Dev Gmbh Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
CN101389653A (zh) 2006-02-23 2009-03-18 菲布雷克斯医疗研究及开发有限责任公司 肽和肽衍生物以及含有它们的药物组合物
WO2007095659A1 (de) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels
EP1987063B1 (en) * 2006-02-23 2009-09-23 Fibrex Medical Research & Development GmbH Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
FR2900657B1 (fr) * 2006-05-03 2009-04-17 Univ Toulouse Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
WO2009038729A2 (en) 2007-09-17 2009-03-26 Regenerx Biopharmaceuticals, Inc. Compositions and methods utilizing fibrin beta chain fragments of the bbeta chain of fibrinogen
FR2908134B1 (fr) * 2007-12-04 2012-10-12 Univ Toulouse 3 Paul Sabatier Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
WO2009096502A1 (ja) * 2008-01-31 2009-08-06 Japan As Represented By President Of National Center Of Neurology And Psychiatry うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
US20090286725A1 (en) * 2008-05-15 2009-11-19 Fibrex Medical Research & Development Gmbh Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US8088890B2 (en) 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010043444A2 (en) * 2008-10-15 2010-04-22 Fibrex Medical Research & Development Gmbh Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof
US20100152832A1 (en) * 2008-12-12 2010-06-17 Medtronic Vascular, Inc. Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US12171802B2 (en) 2016-06-02 2024-12-24 University Of Maryland, Baltimore Compositions for inhibiting fibrin-VLDL receptor-dependent inflammation and methods of treatment
EP3912679A1 (en) * 2020-05-19 2021-11-24 Johann Wolfgang Goethe-Universität Frankfurt am Main Bbeta-15-42 for the treatment of viral endothelitis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927916A (en) * 1984-04-23 1990-05-22 The General Hospital Corporation Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
DE19729591A1 (de) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen
FR2795735B1 (fr) * 1999-07-01 2001-09-07 Univ Toulouse Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide
CA2430972C (en) * 2000-12-12 2014-08-05 Fibrex Medical Research & Development Gmbh Fibrin fragments for treating inflammation
US7201763B2 (en) * 2001-10-24 2007-04-10 Boston Scientific Scimed, Inc. Distal balloon waist material relief and method of manufacture

Also Published As

Publication number Publication date
DK1341819T3 (da) 2006-10-16
CA2430972C (en) 2014-08-05
NO20032656D0 (no) 2003-06-12
EA200300678A1 (ru) 2003-10-30
ATE329614T1 (de) 2006-07-15
EP1586586A2 (de) 2005-10-19
JP4181874B2 (ja) 2008-11-19
US20090137464A1 (en) 2009-05-28
AU2002221316A1 (en) 2002-06-24
CN101676299A (zh) 2010-03-24
HUP0401536A3 (en) 2008-09-29
SI1586586T1 (sl) 2009-08-31
PL362924A1 (en) 2004-11-02
SK7062003A3 (en) 2003-11-04
ES2323963T3 (es) 2009-07-28
MXPA03005218A (es) 2004-12-03
EP1586586B1 (de) 2009-03-11
EP1341819B1 (de) 2006-06-14
EA005576B1 (ru) 2005-04-28
CA2430972A1 (en) 2002-06-20
KR20030060988A (ko) 2003-07-16
ATE425184T1 (de) 2009-03-15
ES2266093T3 (es) 2007-03-01
US20090088384A1 (en) 2009-04-02
BG107891A (bg) 2004-08-31
CN1518558A (zh) 2004-08-04
JP2004527469A (ja) 2004-09-09
ZA200304545B (en) 2004-09-13
IL156360A0 (en) 2004-01-04
PL209752B1 (pl) 2011-10-31
US8067373B2 (en) 2011-11-29
HK1084400A1 (zh) 2006-07-28
NZ550619A (en) 2008-06-30
US20040192596A1 (en) 2004-09-30
EE200300283A (et) 2003-10-15
EP1586586A3 (de) 2006-03-29
PT1586586E (pt) 2010-05-28
CN1518558B (zh) 2010-06-16
WO2002048180A3 (de) 2003-01-30
WO2002048180A2 (de) 2002-06-20
CY1106108T1 (el) 2011-06-08
EP1341819A2 (de) 2003-09-10
HRP20030564A2 (en) 2005-06-30
US20070037749A1 (en) 2007-02-15
US7494973B2 (en) 2009-02-24
SI1341819T1 (sl) 2006-10-31
US7811985B2 (en) 2010-10-12
NO330767B1 (no) 2011-07-11
US7271144B2 (en) 2007-09-18
DE50110182D1 (de) 2006-07-27
BR0116122A (pt) 2003-10-14
YU53803A (sh) 2006-03-03
DK1586586T3 (da) 2009-06-29
IL156360A (en) 2012-12-31
CY1109107T1 (el) 2014-07-02
CZ20031630A3 (cs) 2003-10-15
NO20032656L (no) 2003-06-12
KR100864069B1 (ko) 2008-10-16
HUP0401536A2 (hu) 2004-11-29
PT1341819E (pt) 2006-10-31
DE50114771D1 (de) 2009-04-23

Similar Documents

Publication Publication Date Title
US7811985B2 (en) Therapeutic fibrin-derived peptides and uses thereof
EP0477295B1 (en) Platelet aggregation inhibitors
US5968902A (en) Platelet aggregation inhibitors
Shebuski et al. Demonstration of Ac-Arg-Gly-Asp-Ser-NH2 as an antiaggregatory agent in the dog by intracoronary administration
JP2004527469A6 (ja) ペプチドおよび／またはタンパク質、並びにその治療用および／または予防用医薬成分を調製するための使用
JP3930050B2 (ja) 平滑筋細胞増殖抑制能を有する新規ペプチド
EP0589181A2 (en) Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
EP0725797B1 (en) Bivalent thrombin inhibitors
JPWO1997015598A1 (ja) 新規ペプチド
US5721213A (en) Peptides, active as inhibitors of platelet aggregation
Church et al. Heparin cofactor II and thrombin: heparin-binding proteins linking hemostasis and inflammation
US20050020491A1 (en) Decorin proteoglycan inhibitor of fibrinogen blood clotting
NZ286082A (en) Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment
HK1140212A (en) Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic pharmaceutical
HK1084400B (en) Peptide and/or proteins and their use for the manufacture of a therapeutic and/or preventive medicament

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20111207